Company profile: Grey Wolf Therapeutics
1.1 - Company Overview
Company description
- Provider of antigen modulation therapies that control T cell activation by modulating antigen presentation. Offers ERAP1 and ERAP2 inhibition to generate and upregulate cancer antigens, MHCI-directed therapies to identify novel antigens, and GRWD5769, a selective ERAP1 inhibitor in EMITT-1, an adaptive Phase 1/2 clinical trial assessing monotherapy and combinations with anticancer treatments in solid malignancies.
Products and services
- ERAP1 Inhibition: A mechanism-based approach that targets ERAP1 to generate and upregulate cancer antigens, enhancing tumor recognition and destruction by T cells through modulated antigen presentation
- Clinical Trial EMITT-1: An adaptive Phase 1/2 study assessing GRWD5769 as monotherapy and combined with anticancer treatments in patients with solid malignancies to progress first-in-class antigen modulators
- GRWD5769: A clinical-stage, potent and selective ERAP1 inhibitor being evaluated in a Phase 1/2 clinical trial, engineered to modulate antigen presentation and upregulate cancer antigens to drive T cell activation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Grey Wolf Therapeutics
ImmunoGen
HQ: United States
Website
- Description: Provider of antibody-based anticancer therapeutics using TAP, ELAHERE for platinum-resistant ovarian cancer; investigational IMGN632 for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; mirvetuximab soravtansine (monotherapy, with bevacizumab or carboplatin) for platinum-sensitive ovarian cancers; and IMGN151 for recurrent endometrial and high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoGen company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
Atrin Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development for innovative cancer treatments. The privately held company, based in Doylestown, PA, is engaged in the discovery and development of treatments for cancer, with its most advanced program focused on a new class of highly specific compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atrin Pharmaceuticals company profile →
OncoQuest
HQ: Canada
Website
- Description: Provider of biopharmaceutical products and services, based in Edmonton.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoQuest company profile →
Zionexa
HQ: United States
Website
- Description: Provider of in-vivo biomarkers developed and commercialized to guide targeted therapies in oncology, aiming to improve patients' pathway and quality of life.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zionexa company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Grey Wolf Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Grey Wolf Therapeutics
2.2 - Growth funds investing in similar companies to Grey Wolf Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Grey Wolf Therapeutics
4.2 - Public trading comparable groups for Grey Wolf Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →